Cell therapy for ischemic stroke: are differences in preclinical and clinical study design responsible for the translational loss of efficacy?
Self archived versionfinal draft
MetadataShow full item record
CitationCui, LL. Golubczyk, D. Tolppanen, AM. Boltze, J. Jolkkonen, J. (2019). Cell therapy for ischemic stroke: are differences in preclinical and clinical study design responsible for the translational loss of efficacy?. Annals of neurology, 86 (1) , 5-16. 10.1002/ana.25493.
Cell therapy is an attractive strategy for enhancing post-stroke recovery. Different cell types and several treatment strategies have been successfully applied in animal models, but efficacy in stroke patients has not yet been confirmed. We hypothesize that the significant design differences between preclinical and clinical trials may account for this situation. Using a meta-analysis approach and comparing preclinical with clinical trials, we reveal and discuss preliminary evidence for such design differences. While available datasets are not yet numerous enough to draw definitive conclusions, these findings may represent signposts on the route to efficacy by harmonizing preclinical and clinical study designs.